BactiQuant raises $1.39M to clear debt and fund growth
What's the deal? Danish water-monitoring company BactiQuantDealroom has a profile for this one. Try Dealroom → has completed a US$1.35M (roughly $1.39 million) private placement from eight investors. It issued 4,135,873 new shares at US$0.33 each, diluting existing shareholders by about 9.9%.
Who put in money? The investors include BactiQuant's management and board chair, existing backers, and two new investors. Issuance costs came to about US$27.9K.
What's the money for? The proceeds cover the cost of repaying a US$1.06M EIFO loan, settled on September 30, 2026, and leave capital for growth investment. The company says the move makes it debt-free, cuts financing costs, and improves annual liquidity by about US$322.7K.
What does BactiQuant do? Founded in Denmark in 1999, it develops technology that monitors bacterial contamination levels in water. It serves utilities, aquaculture, waste management companies, and industrial clients across five continents.
Why now? The raise follows a larger US$2.39M private placement in November 2025, which the company said would fund operations through mid-2027. First-half 2026 revenue rose 29% to US$777.3K, while the EBITDA loss narrowed to US$542.7K. Full-year revenue guidance stands at US$1.47M–US$1.91M.
What's next? "The company is now debt-free, and we have strengthened liquidity and have additional capital available," chief executive officer Morten Miller said (translated from Danish). He added that BactiQuant can now focus on selling its product portfolio to customers in pharma and water.
The signal: It is a modest raise — in the 12th percentile by amount — and part of it simply replenishes cash spent on debt repayment. For a growing but still loss-making small-cap, the placement props up the balance sheet rather than signalling a leap in scale.
Read more: ugebrev.dk
Image credit: Klearchos Kapoutsis
